Literature DB >> 15331422

Morphological characterization of Thioflavin-S-positive amyloid plaques in transgenic Alzheimer mice and effect of passive Abeta immunotherapy on their clearance.

Thierry Bussière1, Frédérique Bard, Robin Barbour, Henry Grajeda, Terry Guido, Karen Khan, Dale Schenk, Dora Games, Peter Seubert, Manuel Buttini.   

Abstract

Transgenic mice mimicking certain features of Alzheimer's disease (AD)-pathology, namely amyloid plaques and neurofibrillary tangles, have been developed in an effort to better understand the mechanism leading to the formation of these characteristic cerebral lesions. More recently, these animal models have been widely used to investigate emergent therapies aimed at the reduction of the cerebral amyloid load. Several studies have shown that immunotherapy targeting the amyloid peptide (Abeta) is efficacious at clearing the amyloid plaques or preventing their formation, and at reducing the memory/behavior impairment observed in these animals. In AD, different types of plaques likely have different pathogenic significance, and further characterization of plaque pathology in the PDAPP transgenic mice would enhance the evaluation of potential therapeutics. In the present study, a morphological classification of amyloid plaques present in the brains of PDAPP mice was established by using Thioflavin-S staining. Neuritic dystrophy associated with amyloid plaques was also investigated. Finally, the efficacy of passive immunization with anti-Abeta antibodies on the clearance of Thio-S positive amyloid plaques was studied. Our results show that distinct morphological types of plaques are differentially cleared depending upon the isotype of the antibody.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15331422      PMCID: PMC1618604          DOI: 10.1016/s0002-9440(10)63360-3

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  36 in total

1.  Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease.

Authors:  F Bard; C Cannon; R Barbour; R L Burke; D Games; H Grajeda; T Guido; K Hu; J Huang; K Johnson-Wood; K Khan; D Kholodenko; M Lee; I Lieberburg; R Motter; M Nguyen; F Soriano; N Vasquez; K Weiss; B Welch; P Seubert; D Schenk; T Yednock
Journal:  Nat Med       Date:  2000-08       Impact factor: 53.440

2.  Abeta associated neuropil changes: correlation with neuronal loss and dementia.

Authors:  R B Knowles; T Gomez-Isla; B T Hyman
Journal:  J Neuropathol Exp Neurol       Date:  1998-12       Impact factor: 3.685

3.  Neuropathologic assessment of Alzheimer's disease.

Authors:  S S Mirra; M Gearing; F Nash
Journal:  Neurology       Date:  1997-09       Impact factor: 9.910

Review 4.  The pathogenesis of senile plaques.

Authors:  D W Dickson
Journal:  J Neuropathol Exp Neurol       Date:  1997-04       Impact factor: 3.685

5.  Disaggregation of Alzheimer beta-amyloid by site-directed mAb.

Authors:  B Solomon; R Koppel; D Frankel; E Hanan-Aharon
Journal:  Proc Natl Acad Sci U S A       Date:  1997-04-15       Impact factor: 11.205

6.  Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology.

Authors:  C Sturchler-Pierrat; D Abramowski; M Duke; K H Wiederhold; C Mistl; S Rothacher; B Ledermann; K Bürki; P Frey; P A Paganetti; C Waridel; M E Calhoun; M Jucker; A Probst; M Staufenbiel; B Sommer
Journal:  Proc Natl Acad Sci U S A       Date:  1997-11-25       Impact factor: 11.205

7.  Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse.

Authors:  D Schenk; R Barbour; W Dunn; G Gordon; H Grajeda; T Guido; K Hu; J Huang; K Johnson-Wood; K Khan; D Kholodenko; M Lee; Z Liao; I Lieberburg; R Motter; L Mutter; F Soriano; G Shopp; N Vasquez; C Vandevert; S Walker; M Wogulis; T Yednock; D Games; P Seubert
Journal:  Nature       Date:  1999-07-08       Impact factor: 49.962

8.  A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease.

Authors:  C Janus; J Pearson; J McLaurin; P M Mathews; Y Jiang; S D Schmidt; M A Chishti; P Horne; D Heslin; J French; H T Mount; R A Nixon; M Mercken; C Bergeron; P E Fraser; P St George-Hyslop; D Westaway
Journal:  Nature       Date:  2000 Dec 21-28       Impact factor: 49.962

9.  Comparison of neurodegenerative pathology in transgenic mice overexpressing V717F beta-amyloid precursor protein and Alzheimer's disease.

Authors:  E Masliah; A Sisk; M Mallory; L Mucke; D Schenk; D Games
Journal:  J Neurosci       Date:  1996-09-15       Impact factor: 6.167

10.  Chemical and immunological heterogeneity of fibrillar amyloid in plaques of Alzheimer's disease and Down's syndrome brains revealed by confocal microscopy.

Authors:  M L Schmidt; K A Robinson; V M Lee; J Q Trojanowski
Journal:  Am J Pathol       Date:  1995-08       Impact factor: 4.307

View more
  59 in total

1.  Evodiamine improves congnitive abilities in SAMP8 and APP(swe)/PS1(ΔE9) transgenic mouse models of Alzheimer's disease.

Authors:  Shu-min Yuan; Kai Gao; Dong-mei Wang; Xiong-zhi Quan; Jiang-ning Liu; Chun-mei Ma; Chuan Qin; Lian-feng Zhang
Journal:  Acta Pharmacol Sin       Date:  2011-01-31       Impact factor: 6.150

2.  Accumulation of amyloid precursor protein in the mitochondrial import channels of human Alzheimer's disease brain is associated with mitochondrial dysfunction.

Authors:  Latha Devi; Badanavalu M Prabhu; Domenico F Galati; Narayan G Avadhani; Hindupur K Anandatheerthavarada
Journal:  J Neurosci       Date:  2006-08-30       Impact factor: 6.167

3.  Tau-amyloid interactions in the rTgTauEC model of early Alzheimer's disease suggest amyloid-induced disruption of axonal projections and exacerbated axonal pathology.

Authors:  Amy M Pooler; Manuela Polydoro; Susanne K Wegmann; Rose Pitstick; Kevin R Kay; Laura Sanchez; George A Carlson; Teresa Gomez-Isla; Mark W Albers; Tara L Spires-Jones; Bradley T Hyman
Journal:  J Comp Neurol       Date:  2013-12-15       Impact factor: 3.215

4.  The proof-of-concept of ASS234: Peripherally administered ASS234 enters the central nervous system and reduces pathology in a male mouse model of Alzheimer disease.

Authors:  Mari Paz Serrano; Raquel Herrero-Labrador; Hunter S Futch; Julia Serrano; Alejandro Romero; Ana Patricia Fernandez; Abdelouahid Samadi; Mercedes Unzeta; Jose Marco-Contelles; Ricardo Martínez-Murillo
Journal:  J Psychiatry Neurosci       Date:  2017-01       Impact factor: 6.186

5.  Anti-Abeta42- and anti-Abeta40-specific mAbs attenuate amyloid deposition in an Alzheimer disease mouse model.

Authors:  Yona Levites; Pritam Das; Robert W Price; Marjorie J Rochette; Lisa A Kostura; Eileen M McGowan; Michael P Murphy; Todd E Golde
Journal:  J Clin Invest       Date:  2005-12-08       Impact factor: 14.808

6.  Robust amyloid clearance in a mouse model of Alzheimer's disease provides novel insights into the mechanism of amyloid-beta immunotherapy.

Authors:  Allan Wang; Pritam Das; Robert C Switzer; Todd E Golde; Joanna L Jankowsky
Journal:  J Neurosci       Date:  2011-03-16       Impact factor: 6.167

7.  [F-18]FDDNP microPET imaging correlates with brain Aβ burden in a transgenic rat model of Alzheimer disease: effects of aging, in vivo blockade, and anti-Aβ antibody treatment.

Authors:  Edmond Teng; Vladimir Kepe; Sally A Frautschy; Jie Liu; Nagichettiar Satyamurthy; Fusheng Yang; Ping-Ping Chen; Graham B Cole; Mychica R Jones; Sung-Cheng Huang; Dorothy G Flood; Stephen P Trusko; Gary W Small; Gregory M Cole; Jorge R Barrio
Journal:  Neurobiol Dis       Date:  2011-05-13       Impact factor: 5.996

8.  Fluorescence and autoradiographic evaluation of tau PET ligand PBB3 to α-synuclein pathology.

Authors:  Shunsuke Koga; Maiko Ono; Naruhiko Sahara; Makoto Higuchi; Dennis W Dickson
Journal:  Mov Disord       Date:  2017-04-25       Impact factor: 10.338

9.  Protein mimetic amyloid inhibitor potently abrogates cancer-associated mutant p53 aggregation and restores tumor suppressor function.

Authors:  L Palanikumar; Laura Karpauskaite; Mohamed Al-Sayegh; Ibrahim Chehade; Maheen Alam; Sarah Hassan; Debabrata Maity; Liaqat Ali; Mona Kalmouni; Yamanappa Hunashal; Jemil Ahmed; Tatiana Houhou; Shake Karapetyan; Zackary Falls; Ram Samudrala; Renu Pasricha; Gennaro Esposito; Ahmed J Afzal; Andrew D Hamilton; Sunil Kumar; Mazin Magzoub
Journal:  Nat Commun       Date:  2021-06-25       Impact factor: 14.919

10.  Neuron loss associated with age but not Alzheimer's disease pathology in the chimpanzee brain.

Authors:  Melissa K Edler; Emily L Munger; Richard S Meindl; William D Hopkins; John J Ely; Joseph M Erwin; Elliott J Mufson; Patrick R Hof; Chet C Sherwood; Mary Ann Raghanti
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2020-09-21       Impact factor: 6.237

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.